Apr. 6 at 8:52 PM
$ALT
“Catalysts for Altimmune’s future prospects revolve around positive sentiment shifts in analyst expectations.
H.C. Wainwright increased Altimmune’s price target to
$25, driven by a focus on the Phase 3 MASH program and potential in alcohol-related conditions, outlining promising clinical data for pemvidutide.
Altimmune’s pro forma cash level of
$340 million supports future initiatives despite B. Riley’s conservative price target cut to
$13 amid broader consensus at
$19.12.
Given the encouraging analyst outlooks and strategic focus on high-demand therapeutic areas, Altimmune holds considerable upside potential.
Maintaining support near
$3.00 will be crucial to retaining investor confidence, with resistance expected around
$4.00 as a key short-term target.”
